F-AraG
Phase 2Small molecule
F-AraG is one of 130 small molecule programs targeting COVID-19. It is currently in Phase 2.
5
Indications
11
Total Trials
5
Active Trials
129
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
309 competitors in COVID-19
#DrugCompanyPhaseTrials
1F-AraG
CCellSight Technologies, Inc.
Phase 2
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Activella
Eli LillyPreclinical
Calciferol
Jazz PharmaceuticalsPreclinical
Tricor
JJagotec
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Calcium
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Imaging2 trials
Lymphoma1 trial
Squamous Cell Carcinoma1 trial
Advanced NSCLC1 trial
Non-Small Cell Lung Cancer1 trial
PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT04524195·4 enrolled
5 more indications
Small Cell Lung Cancer1 trial
Radiation Therapy1 trial
Patients With Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for F-AraG. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCellSight Technologies, Inc.